AI Insight
A reanalysis of eight major randomized mammography screening trials suggests that breast cancer overdiagnosis rates may be significantly lower than previously estimated. After accounting for variations in follow-up duration, screening frequency, and post-trial screening practices, researchers found overdiagnosis rates consistent with below 5%, substantially lower than earlier estimates of 30% to 50%. This challenges longstanding concerns about the harms of routine breast cancer screening.
Why it matters
These findings could reshape clinical guidelines and public health recommendations regarding mammography screening. Lower overdiagnosis rates suggest that the balance of benefits versus harms for routine breast cancer screening may be more favorable than recent debates have indicated, potentially supporting broader screening recommendations.
Understand the Science
A new analysis suggests mammograms may lead to far less breast cancer overdiagnosis than some earlier studies indicated. Researchers reexamined all eight major randomized screening trials and accounted for differences in follow-up time, screening frequency, and screening after trials ended. Their results were consistent with an overdiagnosis rate below 5%, rather than estimates approaching 30% to 50%.
Source: A major risk of breast cancer screening may have been overestimated for decades